Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
Wolfram Doehner(Deutsches Herzzentrum der Charité), Milton Packer(Baylor University Medical Center), Stuart Pocock(London School of Hygiene & Tropical Medicine), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), James L. Januzzi(Harvard University), Afshin Salsali(Rutgers, The State University of New Jersey), Javed Butler(Saint Luke's Health System), Carolyn Kaempfer(Rutgers, The State University of New Jersey), João Pedro Ferreira(Inserm), Martina Brueckmann, Stefan D. Anker(Charité - Universitätsmedizin Berlin), Gerasimos Filippatos(National and Kapodistrian University of Athens)
Cited by 122
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k